AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

Rhea-AI Summary

AtriCure, a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 2024 Leerink Partners Healthcare Crossroads Conference.

A fireside chat with AtriCure’s management is scheduled for Wednesday, May 29, 2024, at 10:40 a.m. Central Time. The live audio webcast will be accessible via the 'Investors' section of the company’s website.

Positive

• AtriCure's participation in the 2024 Leerink Partners Healthcare Crossroads Conference is a positive signal, potentially enhancing visibility and investor relations.
• The company is maintaining active engagement with investors and industry stakeholders, which could drive investor confidence and support.

Negative

• No new products, financial data, or business developments were announced in this press release, lacking immediate value to investors.
• Participation in conferences does not guarantee immediate positive impacts on stock performance.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference.

AtriCure’s management is scheduled to participate in a fireside chat on Wednesday, May 29, 2024, at 10:40 a.m. Central Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515941063/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Marissa Bych

Gilmartin Group

Investor Relations

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

What event will AtriCure participate in on May 29, 2024?

AtriCure will participate in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference on May 29, 2024.

Where can I access the AtriCure fireside chat audio webcast?

The live audio webcast of AtriCure's fireside chat will be available on the 'Investors' section of the company’s website.

What is the significance of AtriCure's participation in the Leerink Partners Healthcare Crossroads Conference?

AtriCure's participation in the conference enhances its visibility and engagement with investors and industry stakeholders.

What time is AtriCure's fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference?

AtriCure's fireside chat is scheduled for 10:40 a.m. Central Time on May 29, 2024.